Sanofi's Suppliers recorded an increase in sales by 22.33 % year on year in Q4 2025, sequentially sales grew by 9.18 %, while their net margin rose to 2.36 % year on year, Sanofi's Suppliers improved sequentially profit margin to 9.18 %,
Sanofi's Suppliers recorded an increase in sales by 22.33 % year on year in Q4 2025, sequentially sales grew by 9.18 %, while their net margin rose to 2.36 % year on year, Sanofi's Suppliers improved sequentially profit margin to 2.36 %,
The company manufactures most of its products in-house, producing key active ingredients and main drug products at its own facilities to minimize reliance on external suppliers. It also engages third parties for certain active ingredients, drug products, and medical devices, including a collaboration with Regeneron for monoclonal antibodies. Raw materials for active ingredients are sourced from rigorously selected and approved suppliers. Production sites are classified as global, regional, and local, with vaccine manufacturing located in France, the United States, Canada, India, Mexico, and China. All facilities comply with Good Manufacturing Practice (GMP) standards and hold FDA approvals across various locations in the US, Europe, and Asia. The company seeks to maintain multiple approved plants for key products such as Lovenox and Dupixent. The Opella facilities in France and the US were divested in 2025 as part of the Opella divestment.
Sanofi's Comment on Supply Chain
The company manufactures most of its products in-house, producing key active ingredients and main drug products at its own facilities to minimize reliance on external suppliers. It also engages third parties for certain active ingredients, drug products, and medical devices, including a collaboration with Regeneron for monoclonal antibodies. Raw materials for active ingredients are sourced from rigorously selected and approved suppliers. Production sites are classified as global, regional, and local, with vaccine manufacturing located in France, the United States, Canada, India, Mexico, and China. All facilities comply with Good Manufacturing Practice (GMP) standards and hold FDA approvals across various locations in the US, Europe, and Asia. The company seeks to maintain multiple approved plants for key products such as Lovenox and Dupixent. The Opella facilities in France and the US were divested in 2025 as part of the Opella divestment.
SNY's Suppliers Net Income grew by
SNY's Suppliers Net margin grew in Q4 to
2.36 %
SNY's Suppliers Net Income grew by
SNY's Suppliers Net margin grew in Q4 to 2.36 %
Sanofi's Suppliers Sales Growth
in Q4 2025 by Industry
Sources:
Sanofi's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Sanofi’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
23.02 %